Sorafenib, also known as Nexavar, is a multi-targeted tyrosine kinase inhibitor (TKI) (Llovet et al., 2018) that inhibits tumor cell proliferation by inhibiting kinase activity in the B-Raf, Raf-1, and Ras/Raf/MEK/ERK signaling pathways (Wilhelm et al., 2004) and can also inhibit angiogenesis (Chang et al., 2007), as well as promote apoptosis of tumor cells. The gene discussed is BRAF; the disease is neoplasm.